Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02506569
Other study ID # TA109
Secondary ID
Status Completed
Phase N/A
First received July 14, 2015
Last updated February 6, 2018
Start date January 2015
Est. completion date January 15, 2018

Study information

Verified date February 2018
Source Biotronik SE & Co. KG
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigation is designed to provide supporting evidence for the clinical safety of the Biotronik's new Implantable Cardioverter Defibrillator systems when used under specific 3 Tesla MR conditions .


Recruitment information / eligibility

Status Completed
Enrollment 129
Est. completion date January 15, 2018
Est. primary completion date January 15, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Implanted with Implantable Cardioverter Defibrillator (ICD) system according to Clinical Investigational Plan (CIP)

- ICD system was implanted in the pectoral region

- Implantation at least 5 weeks prior to enrollment date

- Patient body height = 140 cm

- Age = 18 years

- Right Ventricular pacing threshold (at 0.4 ms) measurable and = 2.0 V

- Written informed consent

- Able and willing to complete MRI testing

- Able and willing to complete all testing required by the clinical protocol

- Available for all follow-up visits at the investigational site

Exclusion Criteria:

- Standard contraindication for MRI scans

- Patient shows signs of a twiddler's syndrome, i.e. fiddles with implant

- Explantation, exchange or reposition of ICD or lead within 5 weeks prior to enrollment date

- Charging status of the battery is Elective Replacement Indicator (ERI) or End of Service (EOS)

- MRI scan within 5 weeks prior to enrollment date

- R-wave sensing amplitude < 6.5 millivolt

- Lead impedance less than 200 or greater than 1500 Ohm

- Life expectancy of less than six months

- Cardiac surgery in the next six months

- Pregnant or breastfeeding

- Participation in another interventional clinical investigation

Study Design


Related Conditions & MeSH terms

  • Safety of MR (Magnetic Resonance)-Conditional ICDs

Intervention

Device:
Implantable Cardioverter Defibrillator therapy
Tachycardia Fast Heart Beat
Other:
Magnetic Resonance Imaging (MRI)
MRI scan of the head and lower body parts

Locations

Country Name City State
Australia Flinders Medical Centre Bedford Park
Australia Royal North Shore Hospital Sydney
Australia Westmead Hospital Westmead
Austria Allgemeines Krankenhaus Linz Linz
Austria Landesklinikum St. Pölten St. Pölten
Germany Deutsches Herzzentrum Berlin Berlin
Germany Klinikum Coburg Coburg
Germany Uniklinikum Düsseldorf Düsseldorf
Germany Universitätsklinikum Göttingen Göttingen
Germany St. Bonifatius Hospital Lingen
Singapore National Heart Centre Singapore
Switzerland Stadtspital Triemli Zürich

Sponsors (1)

Lead Sponsor Collaborator
Biotronik SE & Co. KG

Countries where clinical trial is conducted

Australia,  Austria,  Germany,  Singapore,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serious Adverse Device Effect (SADE)-free rate of implantable cardioverter defibrillators and leads possibly or securely related to the MRI procedure 1 Month
Primary Increase in pacing thresholds ratios measured between 1-month post-MRI and pre-MRI Evaluate the percentage of ICD leads with an increase in the pacing threshold ratio measured between the Pre-MRI and 1-month post-MRI 1 Month
Primary Decrease in sensing amplitude ratios between 1-month post-MRI and pre-MRI Evaluate the percentage of ICD leads with a decrease in the sensing amplitude ratio measured between the Pre-MRI and 1-month post-MRI 1 Month